{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:30Z","timestamp":1793898270701,"version":"4.8.0"},"reference-count":111,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. The proposed pathophysiological hypotheses of SLE are numerous, involving both innate and adaptive abnormal immune responses. SLE is characterized by the overproduction of different autoantibodies that form immune complexes, which cause damage in different organs. Current therapeutic modalities are anti-inflammatory and immunosuppressive. In the last decade, we have witnessed the development of many biologicals targeting different cytokines and other molecules. One of them is interleukin-17 (IL-17), a central cytokine of a proinflammatory process that is mediated by a group of helper T cells called Th17. Direct inhibitors of IL-17 are used in psoriatic arthritis, spondyloarthritis, and other diseases. Evidence about the therapeutic potential of Th17-targeted therapies in SLE is scarce, and probably the most promising is related to lupus nephritis. As SLE is a complex heterogeneous disease with different cytokines involved in its pathogenesis, it is highly unlikely that inhibition of only one molecule, such as IL-17, will be effective in the treatment of all clinical manifestations. Future studies should identify SLE patients that are eligible for Th17-targeted therapy.<\/jats:p>","DOI":"10.3390\/cimb45050275","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:45:47Z","timestamp":1684205147000},"page":"4331-4343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?"],"prefix":"10.3390","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-9633","authenticated-orcid":false,"given":"Marin","family":"Petri\u0107","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, University Hospital of Split, Center of Excellence for Systemic Sclerosis Ministry of Health Republic of Croatia, \u0160oltanska 1, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-6800","authenticated-orcid":false,"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, University Hospital of Split, Center of Excellence for Systemic Sclerosis Ministry of Health Republic of Croatia, \u0160oltanska 1, 21000 Split, Croatia"},{"name":"Department of Internal Medicine, School of Medicine, University of Split, \u0160oltanska 2, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Papp, K., V\u00e9gh, P., H\u00f3bor, R., Szittner, Z., Vok\u00f3, Z., Podani, J., Czirj\u00e1k, L., and Prechl, J. (2012). Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein bindin analysis on antigen microarrays. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044824"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1177\/0961203313500548","article-title":"Systemic lupus erythematosus (SLE) in the eastern region of Saudi Arabia. A comparative study","volume":"22","author":"Abid","year":"2013","journal-title":"Lupus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","article-title":"Biologics in the treatment of Sjogren\u2019s syndrome, systemic lupus erythematosus, and lupus nephritis","volume":"32","author":"Narain","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/08916930701510673","article-title":"Complement deficiencies and systemic lupus erythematosus","volume":"40","author":"Truedsson","year":"2007","journal-title":"Autoimmunity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"432595","DOI":"10.1155\/2011\/432595","article-title":"Inflammatory Cytokines in Systemic Lupus Erythematosus","volume":"2011","author":"Ohl","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/acr2.11414","article-title":"Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval","volume":"4","author":"Loncharich","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"ref_10","first-page":"CD010668","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/1756-185X.12463","article-title":"Current role of rituximab in systemic lupus erythematosus","volume":"18","author":"Mok","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 Family of Cytokines in Health and Disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: Cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ni.2797","article-title":"Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR\u03b3t and dectin-2","volume":"15","author":"Taylor","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.micinf.2019.06.009","article-title":"The IL-23\/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies","volume":"21","author":"Bianchi","year":"2019","journal-title":"Microbes Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: Prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.it.2021.09.005","article-title":"ROR\u03b3t protein modifications and IL-17-mediated inflammation","volume":"42","author":"Kumar","year":"2021","journal-title":"Trends Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.07.004","article-title":"Post-translational regulation of ROR\u03b3t-A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases","volume":"30","author":"Rutz","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1038\/s41598-021-90497-9","article-title":"Preclinical and clinical characterization of the ROR\u03b3t inhibitor JNJ-61803534","volume":"11","author":"Xue","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjd.14814","article-title":"Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis","volume":"176","author":"Epstein","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000484520","article-title":"Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials","volume":"233","author":"Naik","year":"2017","journal-title":"Dermatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: A systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1093\/rheumatology\/keab193","article-title":"Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients","volume":"60","author":"Onac","year":"2021","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12935-022-02528-8","article-title":"The role of Th17 cells in the pathogenesis and treatment of breast cancer","volume":"22","author":"Karpisheh","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"624971","DOI":"10.3389\/fimmu.2020.624971","article-title":"Current Insights and Future Prospects for Targeting IL-17 to Treat Patients with Systemic Lupus Erythematosus","volume":"11","author":"Koga","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916934.2015.1037441","article-title":"Interleukin-17 in systemic lupus erythematosus: A comprehensive review","volume":"48","author":"Li","year":"2015","journal-title":"Autoimmunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"823085","DOI":"10.1155\/2012\/823085","article-title":"Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new","volume":"2012","author":"Alunno","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1400931","article-title":"IL-17 promotes murine lupus","volume":"193","author":"Amarilyo","year":"2014","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wen, Z., Xu, L., Xu, W., Yin, Z., Gao, X., and Xiong, S. (2013). Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058161"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0961203312451200","article-title":"Gene expression of cytokines (TNF-\u03b1, IFN-\u03b3), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus","volume":"21","author":"Rana","year":"2012","journal-title":"Lupus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","article-title":"Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity","volume":"72","author":"Talaat","year":"2015","journal-title":"Cytokine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3946320231154998","DOI":"10.1177\/03946320231154998","article-title":"Crosstalk between miR-146a and pro-inflammatory cytokines in patients with systemic lupus erythematosus","volume":"37","author":"Talaat","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/08820139.2019.1699107","article-title":"Elevated Circulating Interleukin-17 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis","volume":"49","author":"Shen","year":"2020","journal-title":"Immunol. Invest."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5604\/17322693.1111127","article-title":"Peripheral blood Th17\/Treg imbalance in patients with low-active systemic lupus erythematosus","volume":"68","author":"Kosmaczewska","year":"2014","journal-title":"Postepy Hig Med. Dosw. (Online)"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/annrheumdis-2021-220363","article-title":"Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity","volume":"80","author":"Jesus","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/jdv.13769","article-title":"Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus","volume":"30","author":"Patsinakidis","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: Toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: Role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e12933","DOI":"10.1111\/sji.12933","article-title":"The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions","volume":"93","author":"Zhou","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"Kalunian","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jdcr.2019.01.015","article-title":"Ustekinumab-induced subacute cutaneous lupus","volume":"5","author":"Tierney","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/09612033221095692","article-title":"Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature","volume":"31","author":"Hsieh","year":"2022","journal-title":"Lupus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jdcr.2020.02.013","article-title":"Secukinumab-induced chronic discoid lupus erythematosus","volume":"6","author":"Chatzimichail","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1097\/RHU.0000000000001511","article-title":"Secukinumab-Induced Lupus Erythematosus: A Case Report and Literature Review","volume":"27","author":"Kaler","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1111\/dth.13417","article-title":"Secukinumab-induced subacute cutaneous lupus erythematosus","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/ced.14583","article-title":"Brodalumab-induced subacute cutaneous lupus erythematosus","volume":"46","author":"Ang","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1080\/09546634.2022.2062281","article-title":"The dark side of the moon: The immune-mediated adverse events of IL-A\/IL-17R inhibition","volume":"33","author":"Messina","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1346-8138.15645","article-title":"Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab","volume":"48","author":"Akaji","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/24725625.2020.1717741","article-title":"Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile","volume":"4","author":"Sato","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jdcr.2022.05.039","article-title":"New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis","volume":"25","author":"Barber","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e13070","DOI":"10.1111\/dth.13070","article-title":"Refractory lupus erythematosus tumidus responsive to tildrakizumab","volume":"32","author":"Ismail","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.berh.2011.10.018","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions. Jaccoud\u2019s arthropathy","volume":"25","author":"Santiago","year":"2011","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1177\/09612033211051637","article-title":"Erosive arthritis in systemic lupus erythematosus: Not only Rhupus","volume":"30","author":"Ceccarelli","year":"2021","journal-title":"Lupus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cei.13585","article-title":"Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid","volume":"205","author":"Sippl","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis","volume":"11","author":"Vecellio","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Tsukazaki, H., and Kaito, T. (2020). The Role of the IL-23\/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176401"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jaci.2013.03.015","article-title":"Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated disease","volume":"131","author":"Hirahara","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2010.06.001","article-title":"Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells","volume":"32","author":"Wu","year":"2010","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40744-022-00442-z","article-title":"A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus","volume":"9","author":"Vital","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.nmd.2014.06.432","article-title":"The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications","volume":"24","author":"Moran","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11926-012-0242-x","article-title":"Interleukin-17 in inflammatory myopathies","volume":"14","author":"Tournadre","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: Core Curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","article-title":"The role of IL-23\/IL-17 axis in lupus nephritis","volume":"183","author":"Zhang","year":"2009","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.38955","article-title":"Function of the Th17\/interleukin-17A immune response in murine lupus nephritis","volume":"67","author":"Schmidt","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.4049\/jimmunol.0903595","article-title":"Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice","volume":"184","author":"Kyttaris","year":"2010","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Zickert, A., Amoudruz, P., Sundstr\u00f6m, Y., R\u00f6nnelid, J., Malmstr\u00f6m, V., and Gunnarsson, I. (2015). IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0070-7"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/1756-185X.12393","article-title":"Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis","volume":"19","author":"AlFadhli","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_75","first-page":"2279","article-title":"Analysis of expression levels of IL-17 and IL-34 and influencing factors for prognosis in patients with lupus nephritis","volume":"17","author":"Cheng","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2019.04.002","article-title":"Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients","volume":"210","author":"Dedong","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.007","article-title":"The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis","volume":"76","author":"Galil","year":"2015","journal-title":"Cytokine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"654912","DOI":"10.3389\/fmed.2021.654912","article-title":"The Th17\/IL-17 Axis and Kidney Diseases, with Focus on Lupus Nephritis","volume":"8","author":"Paquissi","year":"2021","journal-title":"Front. Med."},{"key":"ref_79","unstructured":"(2023, February 18). Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination with SoC Therapy, in Patients with Active Lupus Nephritis (SELUNE), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04181762."},{"key":"ref_80","unstructured":"(2023, February 18). A Study of Guselkumab in Participants with Active Lupus Nephritis (ORCHID-LN), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04376827."},{"key":"ref_81","first-page":"e17198","article-title":"Secukinumab on Refractory Lupus Nephritis","volume":"13","author":"Costa","year":"2021","journal-title":"Cureus"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0961203318762598","article-title":"A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab","volume":"27","author":"Satoh","year":"2018","journal-title":"Lupus"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jdcr.2019.05.022","article-title":"New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus","volume":"5","author":"Scott","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3899\/jrheum.170737","article-title":"Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus","volume":"45","author":"Yang","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Mariz","year":"2013","journal-title":"Clinics"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e124575","DOI":"10.1172\/jci.insight.124575","article-title":"Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients","volume":"4","author":"Guthridge","year":"2019","journal-title":"JCI Insight"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1177\/0091270011413894","article-title":"Characterizing the impact of renal impairment on the clinical pharmacology of biologics","volume":"52","author":"Meibohm","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","article-title":"A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"15","author":"Ho","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar4277","article-title":"Clinical associations of serum interleukin-17 in systemic lupus erythematosus","volume":"15","author":"Vincent","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"gmr7626","DOI":"10.4238\/gmr.15027626","article-title":"Balance between inflammatory and regulatory cytokines in systemic lupus erythematosus","volume":"15","author":"Yao","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clim.2015.01.010","article-title":"Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases","volume":"157","author":"Ichinose","year":"2015","journal-title":"Clin. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e91663","DOI":"10.1172\/jci.insight.91663","article-title":"IL-23R-activated STAT3\/STAT4 is essential for Th1\/Th17-mediated CNS autoimmunity","volume":"2","author":"Lee","year":"2017","journal-title":"JCI Insight"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jpsychires.2012.08.016","article-title":"Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse","volume":"46","author":"Borovcanin","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"ref_94","first-page":"e22938","article-title":"A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus","volume":"14","author":"Santacruz","year":"2022","journal-title":"Cureus"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2011.060822","article-title":"Production of the effector cytokine interleukin-17, rather than interferon-\u03b3, is more strongly associated with autoimmune hemolytic anemia","volume":"97","author":"Hall","year":"2012","journal-title":"Haematologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13052-021-01131-3","article-title":"IL-23\/Th17 pathway and IL-17A gene polymorphism in Egyptian children with immune thrombocbytopenic purpura","volume":"47","author":"Ismail","year":"2021","journal-title":"Ital. J. Pediatr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/MPH.0000000000002108","article-title":"Increased Expression of IL-17A and IL-17F Is Correlated with RUNX1 and ROR\u03b3T in Pediatric Patients with Primary Immune Thrombocytopenia","volume":"43","author":"Elnaenaey","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/16078454.2021.1974200","article-title":"Decreasing lncRNA PVT1 causes Treg\/Th17 imbalance via NOTCH signaling in immune thrombocytopenia","volume":"26","author":"Yu","year":"2021","journal-title":"Hematology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"421","DOI":"10.14715\/cmb\/2021.67.5.54","article-title":"The relationship between different interleukins and T helper cells count in patients with immune thrombocytopenia","volume":"67","author":"Li","year":"2022","journal-title":"Cell. Mol. Biol."},{"key":"ref_100","first-page":"291","article-title":"Interleukin-17A and -17F Gene Polymorphisms in Chinese Population with Chronic Immune Thrombocytopenia","volume":"46","author":"Liu","year":"2016","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.4049\/jimmunol.179.12.8274","article-title":"IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice","volume":"179","author":"Smith","year":"2007","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/ki.2010.84","article-title":"Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production","volume":"78","author":"Ouyang","year":"2010","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/1060028020907202","article-title":"Secukinumab-Induced Acute Autoimmune Hemolytic Anemia","volume":"54","author":"Rivas","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_106","first-page":"1972","article-title":"Successful use of Ustekinumab in a Patient with Psoriasis, Psoriatic Arthritis and Systemic Lupus Erythematosus: A Case report and Review of literature","volume":"1","author":"Kugasia","year":"2017","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.transci.2012.06.024","article-title":"Ustekinumab associated thrombotic thrombocytopenic purpura","volume":"47","author":"Huang","year":"2012","journal-title":"Transfus. Apher. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-1987","article-title":"Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate","volume":"95","author":"Philippe","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ajg.2022.06.008","article-title":"Hypersplenism and thrombocytopenia after exposure to ustekinumab in a patient with Crohn\u2019s disease","volume":"23","author":"Altuwaijri","year":"2022","journal-title":"Arab. J. Gastroenterol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/14712598.2021.1853096","article-title":"The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?","volume":"21","author":"Isenberg","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of Efficacy and Safety of Ustekinumab through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients with Active Systemic Lupus Erythematosus","volume":"72","author":"Hahn","year":"2020","journal-title":"Arthritis Rheumatol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/5\/275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:10Z","timestamp":1760124910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/5\/275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cimb45050275"],"URL":"https:\/\/doi.org\/10.3390\/cimb45050275","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}